Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis
Conclusion: Patients’ adherence to medication treatment was low and may be associated with social, physical, and cognitive measures. (Source: Journal of Neuroscience Nursing)
Source: Journal of Neuroscience Nursing - September 8, 2018 Category: Neuroscience Tags: Article Source Type: research
Efficacy and safety of monoclonal antibody therapies for relapsing remitting multiple sclerosis: a network meta-analysis
ConclusionThis network meta-analysis provided a comprehensive summary of efficacy and safety of monoclonal antibodies for RRMS, which might provide a reference for treatment. More direct comparison studies are warranted. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - August 30, 2018 Category: Neurology Source Type: research
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study
ConclusionIn PREFERMS, fingolimod was associated with better treatment retention than iDMTs in African-American patients. Optimal outcomes in the management of multiple sclerosis depend on good persistence with treatment, and this is particularly important in patient populations at increased risk of a rapidly progressing disease course. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - July 20, 2018 Category: Neurology Source Type: research
Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African–American patients: A subgroup analysis of a randomized phase 4 study
Conclusion: In PREFERMS, fingolimod was associated with better treatment retention than iDMTs in African–American patients. Optimal outcomes in the management of multiple sclerosis depend on good persistence with treatment, and this is particularly important in patient populations at increased risk of a rapidly progressing disease course.Trial Registration: NCT01623596.Funding: Novartis Pharmaceuticals Corporation. (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - July 11, 2018 Category: Neurology Source Type: research
Neutralizing antibody production against Rebif ® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
CONCLUSION: Receiving interferon beta-1a for >24 months is correlated with higher possibility of NAb production. The type of IFN-β used in the study had no significant impact on NAb positivity. In addition, both groups had comparable EDSS score changes, and NAb status of patients was correlated with their EDSS score.
PMID: 29990690 [PubMed - as supplied by publisher] (Source: International Immunopharmacology)
Source: International Immunopharmacology - July 7, 2018 Category: Allergy & Immunology Authors: Shokrollahi Barough M, Ashtari F, Sadat Akhavi M, Asghari N, Mosayebi G, Mirmohammadkhani M, Kokhaei N, Bahraminia F, Ajami A, Kokhaei P Tags: Int Immunopharmacol Source Type: research
